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Determination of feline leukemia proviral sequences in naturally infected cats
Abstract
Felines are susceptible to many different viruses throughout their lifetime, one being Feline Leukemia
Virus (FeLV). FeLV is a transmittable RNA retrovirus that inhabits the cells of feline species' immune
systems leading to possible infections and diseases such as seizures and other neurological disorders,
anemia, stomatitis, enteritis, and lymphoma. There are four different types of this virus, FeLV-A, FeLV-B,
FeLV-C, or FeLV-T, that enter cells via different cellular receptors causing different symptoms. FeLV-A is
horizontally transmittable, and all FeLV-positive cats carry this form. Of the subtypes, FeLV-B is the most
common, being found in approximately 50% of all cases, most often in cats with tumors and other
abnormal tissue growths. The aim of this research was to determine the proviral sequences of FeLV-B in
multiple tissue samples collected from a FeLV positive cat. Genomic DNA from multiple tissue samples
of a naturally infected cat with FeLV-B was extracted and digested with a set of restriction enzymes.
Adapters were ligated to known sequences using genome walking and PCR was used to amplify
fragments containing proviral FeLV. Samples were sent for sequencing, and the results used to design
new primers for further work. It was hypothesized that of the six tissue samples, the tumor samples
would show mutations and/or rearrangements not observed in other tissues. FeLV-B was confirmed in
five of the six tissue samples extracted. When comparing known FeLV-A and -B sequences, the samples
tissues were more closely related to the known FeLV-B. Variations in the tumor samples were observed in
the nucleotide sequences and when these variations were altered, mutations within the amino acid
sequences were observed.
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Abstract
Felines are susceptible to many different viruses throughout their lifetime, one being
Feline Leukemia Virus (FeLV). FeLV is a transmittable RNA retrovirus that inhabits the cells of
feline species' immune systems leading to possible infections and diseases such as seizures and
other neurological disorders, anemia, stomatitis, enteritis, and lymphoma. There are four
different types of this virus, FeLV-A, FeLV-B, FeLV-C, or FeLV-T, that enter cells via different
cellular receptors causing different symptoms. FeLV-A is horizontally transmittable, and all
FeLV-positive cats carry this form. Of the subtypes, FeLV- B is the most common, being found
in approximately 50% of all cases, most often in cats with tumors and other abnormal tissue
growths. The aim of this research was to determine the proviral sequences ofFeLV-B in multiple
tissue samples collected from a FeLV positive cat. Genomic DNA from multiple tissue samples
of a naturally infected cat withFeLV-B was extracted and digested with a set of restriction
enzymes. Adapters were ligated to known sequences using genome walking and PCR was used
to amplify fragments containing proviralFeLV. Samples were sent for sequencing, and the
results used to design new primers for further work. It was hypothesized that of the six tissue
samples, the tumor samples would show mutations and/or rearrangements not observed in other
tissues. FeLV-B was confirmed in five of the six tissue samples extracted. When comparing
known FeLV-A and -B sequences, the samples tissues were more closely related to the known
FeLV-B. Variations in the tumor samples were observed in the nucleotide sequences and when
these variations were altered, mutations within the amino acid sequences were observed.
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Introduction
Feline leukemia virus is a simple gamma retrovirus that impacts the health of both
domestic and wild cat populations. This retrovirus is horizontally transmitted through direct
contact; frequently contaminated saliva from viraemic cats is transferred into the oropharynx of
susceptible cats. With horizontal transmission from cat to cat, it has been estimated that nearly
half of the urban domestic cat population will become infected with FeLV during a lifetime.Pl
Once the virus integrates itself into the host's DNA, it remains there until the host passes away.
Due to this characteristic, the virus can be problematic for large cat species such as Puma
conco/or coryi, the Florida puma. This species became endangered in the late 1990s and with the

identification of FeLV antigen-positive pumas during the capture season in 2002-2003, an
investigation was launched to observe the progression of FeLV in the species. It was found that
between January 1990 and April 2007, there was an increase in the proportion of pumas testing
antibody-positive for FeLV. Vaccination was used to try to treat the epizootic and although there
have been no new reported cases since July 2004, there is still a chance the virus could be
reintroduced to the species.l2J
In 1964, William Jarrett discovered feline leukemia virus, which was the first identified
feline retrovirus.[JJ Similar to the retrovirus of rodents, gibbons and koalas, FeLV is a simple
gamma retrovirus.141 Although there are seven types of retroviruses, they all contain similar
genomic structures. The genome consists of three mutual genes, pol, gag, and env, that sit
between the upstream and downstream long terminal repeats (LTRs). The pol gene encodes those
enzymes that are needed for replication and integration, such as reverse transcriptase and
integrase. The gag gene encodes the main proteins of the virion, and the env gene encodes the
glycoproteins of the envelope, the surface glycoproteins (SU) and the transmembrane protein
1

(TM)Y1 Variations in the SU affect receptor selection and binding affinity which then influence
the rate of tissue tropism, virus spread and disease variety.ISi The inner core of FeLV is made
from p27, the capsid protein, which is enclosed by two envelope glycoproteins, the surface gp70,
and the transmembrane protein pl 5E.131
Figure 1 shows the structure of proviral FeLV. The LTR of FeLV in natural isolates
shows significant genetic variation and these variations in LTRs have been associated with
certain disease outcomes. For example, FeLV proviruses typically contained only a single copy
of the enhancer in LTRs when obtained from non-T-cell malignancies. But for the FeLV
proviruses cloned directly from thymic lymphomas of T-cell origin, LTRs contain two or three
tandemly repeated enhancers.161
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Figure 1: Integrated FeLV proviral DNA. The double-stranded DNA
provirus is integrated into the host genome after reverse transcription of
viral DNA.

While feline retroviruses contain similar genomic structure, there are multiple types that
help distinguish them, such as exogenous and endogenous viruses. An exogenous virus is one
that is transmitted horizontally. Unlike an exogenous virus that is caused by an agent outside the
host, an endogenous virus is one that is transmitted in the germ-line DNA of an infected host to
another Pl Endogenous viruses are present in germ-lines due to residuals of ancient infections of
animals by retroviruses. One type of the endogenous viruses in cats includes those endogenous
FeLV-like genomes that have at least two families. These genomes contain many stop codons
2

and are defective. They are never found as infectious viruses even though they, at times, express
proteins such as envelope glycoproteins. The second endogenous virus, RD114, is not defective
and while it may be expressed in cats, it rarely spreads in vivo or in vitro due to the lack of
receptors for the virus in most cat cells.131
During the first stage of the viral replicative cycle, an RNA genome with encoded
genetic information of the retrovirus is copied into DNA assisted by reverse transcriptase. This
enzyme disrupts the typical cellular flow of genetic information from DNA to RNA to protein.
The DNA copy of the RNA genome is synthesized and then incorporated into the target cell's
genome as a provirus. Integrase, a viral enzyme, aids in this process. For the lifespan of the
infected cell, the provirus persists in the genomic DNA, providing a template for viral gene
expression, leading to progeny virions and virus shedding. 141

Figure 2: FeLV Structure. FeLV is a gamma-retrovirus measuring 110 millimicrons
in diameter. The envelope consists of surface and transmembrane proteins, which
allows the virus access to its host cell.
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FeLV does not carry genetic infonnation that could code for its disease potential; it only
encodes the genes needed for its structure and replication. Despite the simplicity of theFeLV
genome, it actually occurs as a complex family of closely related viruses rather than a single
genetic species. This is due to genetic variation that takes place during replication in vivo through
error-prone reverse transcription as well as recombination with endogenousFeLV-related
sequences in the cat genome, leading to a virus population that is genetically diverse. Changes
also occur by rearrangements or deletions during proviral DNA integration into the host cell, and
through viral transduction, when the host genome is obtained by the virus and it is copied into
other host cells in conjunction with the viral genome. The effect of these changes has led to three
sub-types of feline leukemia that can arise in cats already infected with the virus,FeLV-A,
includingFeLV-B, -C, and-T.lSJ
Feline leukemia virus is separated into four distinct subtypes: A, B, C, and T. Due to the
differences in cellular receptors used to enter the host, different symptoms arise from each strain.
Any cat diagnosed with feline leukemia virus carriesFeLV-A, which is responsible for interhost
transmission and is the only one to be horizontally transmitted. FeLV-B is proposed to be a
recombination ofFeLV-A with endogenousFeLV-related env sequences and is found in
approximately 50% ofFeLV positive cats that are otherwise healthy. Isolates of FeLV-C are rare
and only occur withFeLV-A or the combination ofFeLV-A andFeLV-B.FeLV-T is a T-cell
tropic, cytopathic virus that has been isolated from nonvirulent fonns ofFeLV-A. Table I below
shows cell entry methods, symptoms, and unique features of each subtype for better clarification
of the differences.[SJ
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Table 1: FeLV Subtypes. The cell entry methods, symptoms, and unique features of FeLV
subtypes compared to clarify differences between each subtype.19,toJ

Subtvne
FeLV-A

FeLV-B
FeLV-C
FeLV-T

Cell Entrv Methods

Svmotoms

Thiamine transport
protein receptor, THTRI

Hematopoietic,
neoplasia

Inorganic phosphate
transporter PiTl and PiT�
Heme exporting protein
receptor, FLVCRI
PiTl and co-receptor
FeLiX

Neoplastic diseases
Severe anemia,
leukemia
Fever, diarrhea,
neutropenia,
lymphopenia

Uniaue Features

FeLV-A cells remain susceptible
to FeLV-8, so vaccinations with
this strain prevents infection by
all 3 subtypes
Non-pathogenic on its own, only
when recombined with FeLV-A
Developed anemia is typically
fatal within 1 month
Infects T lymphocytes leading to
severe immunosuppression

For this study, tissue samples from necropsy of a cat diagnosed withFeLV-A and FeLVB from Leuk's Landing Leukemia Rescue were used. The focus of the study was to verify the
presence ofFeLV-8 in the tissue samples obtained and to determine unique mutations present in
the variable regions of the envelope and long terminal repeats. Previous studies have shown that
these unique sequences can significantly alter disease progression. By identifying previously
unknown variations, new information about FeLV can be exposed leading to better
understanding of the virus.

Methods and Materials
Extraction of Genomic DNA from Tissue Samples
A Clontech Nucleospin Tissue Genomic DNA Extraction Kit was used to extract tissue
samples as described below.

s

Preparation of Tissue Lysates

Tissue samples, about 25 mg, were cut into small pieces and placed in a 1.5 mL
microcentrifuge tube. Aliquots of 180 µL of Genomic Digestion Buffer and 20 µL of Proteinase
K were added to each tube. The samples were vortexed gradually to mix and incubated at 57°C
overnight. The samples were then vortexed briefly for 30 seconds and placed back into the water
bath for roughly 15 minutes before being centrifuged for 3 minutes at 1400 rpm. After
centrifuging, the supemate was placed in a new sterile tube along with 20 µL RNase A. Each was
vortexed for no more than 30 seconds and then allowed to sit for 2 minutes at room temperature.
Aliquots of 200 µL of Genomic Lysis/Binding buffer and 200 µL of 100% ethanol were added to
all tubes, which were then vortexed for 5 seconds.
Binding, Washing, and Eluting DNA from Tissue Lysates

Samples were transferred to a NucleoSpin spin column with collection tube and 640 µL
of Lysate were added. After centrifuging for 1 minute at 10,000 rpm, the flow-through was
discarded and 500 µL Wash Buffer 1 were added. Samples were centrifuged again at 10,000 rpm
for 1 minute and flow-through discarded. An aliquot of 500 µL Wash Buffer 2 was added, the
columns were centrifuged for 3 minutes at 14,000 rpm, with flow-through discarded. The
collection tubes were discarded and the dry spin columns were placed in clean 1.5 mL tubes. A
volume of 100 µL Elution Buffer was added to each sample, which were then incubated at room
temperature for 1 minute. Samples were centrifuged for 1 minute at 14,000 rpm to collect DNA
eluent. All samples were stored at -20°C until used.
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Polymerase Chain Reaction Primers
Table 2 shows PCR primers used to confirm the presence of FeLV in the tissue samples.
Table 2: PCR Primers. Primers used in primary PCR.
B5F
B5R

TCCCGAGTAACACCTCACCATTCCCA
AGCCTGGTGGGTCTTAGGAACAGTCC

Polymerase Chain Reaction
Table 3 shows the general PCR mixture for one sample.
Table 3: Conditions used to Primary and Secondary PCR processes.
Priman PCR
19.5 uLH20
2.5 µL 1 Ox Advantage 2 PCR Buffer
0.5 uLdNTP
0.5 uLAdvantage 2 Polymerase Mix (50x)
0.5 uLPrimer
1 uLtissue extract
24.5 uLtotal/ rxn

Secondan, PCR
19.5 uLH20
2.5 uL 1Ox Advantage 2 PCR Buffer
0.5 uLdNTP
0.5 uLAdvantage 2 Polymerase Mix (50x)
0.5 uLPrimer
1 uLtissue extract
24.5 uLtotal/ rxn

Thermocycler conditions for both primary and secondary PCR are listed in Table 4 below. Once
cycles were complete, samples were placed in -20°C refrigerator until used.
Table 4: PCR conditions used for thennocycler.
Priman, PCR

Secondan, PCR
Hot start at 94°C for 1 minute
7 cycles: 94°C 25 sec
5 cycles: 94°C 25 sec
72°C 3 min
72°C 3 min
°
32 cycles: 94 C 25 sec
20 cycles: 94°C 25 sec
67 °C 3 min
67°C 3 min
°
67 C for additional 7 minutes after final cvcle
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Purification of PCR Amplicons
A Clontech NucleoSpin Gel and PCR Clean-Up Kit was used to purify PCR products.
Sample volumes were adjusted to 50 µL total volume, using 1 5 µL of PCR sample and 35 µL of
water, then mixed with 1 00 µL of Buffer NTI. The 1 50 µL mixtures were loaded into cleanup
columns with collection tubes and centrifuged for 30 seconds at 1 3,000 rpm; flow-through was
discarded and columns were placed back into collection tubes. A volume of 700 µL of Buffer
NT3 was added to the columns, which were then centrifuged for 30 seconds at 1 3,000 rpm. The
flow-through was discarded, and this step was repeated. Samples were centrifuged for 1 minute
at 1 3,000 rpm to remove any excess Buffer NT3. The spin tubes were placed in new clean 1 .5
mL microcentrifuge tubes and incubated on a hot plate for 4 minutes at 70°C, with lids cracked.
Aliquots of 20 µL of Buffer NE were then added and samples were incubated at room
temperature for 1 minute. The columns were centrifuged for 1 minute at 13,000 rpm, allowing
1.5 mL tubes to collect PCR clean up eluent. Columns were discarded and the samples were
placed in a -20°C refridgerator until used.

Digestion of DNA for Genome Walking Libraries
DNA templates were digested with restriction enzymes Oral, EcoRV, Pvull, and Stul
according to the Genome Walker manual (Clontech). For each digestion, 25 µL of DNA extract
were mixed with 8 µL of restriction enzyme ( 1 0 units/µL), IO µL of buffer ( IOx), and 57 µL of
deionized water. The tubes were inverted several times to mix, and incubated at 37°C for 2
hours. After vortexing gently for 1 0- 1 5 s, the reactions were incubated overnight at 37°C.

8

Post-Digestion Purification
A NucleoSpin® Gel and PCR Clean-up Kit (Clontech) was used to purify the digested
DNA samples. Spin columns were placed into collection tubes (2 mL) and 500-700 µL of sample
digest were loaded. The columns were centrifuged for 30 s at 1 1,000 x g, and the flow-through
was discarded. A volume of 700 µL Buffer NT3 was added to each and the columns were
centrifuged for 30 s at 1 1 ,000 x g. The flow-through was discarded. The columns were
centrifuged again for 1 min at 1 1,000 x g to remove Buffer NT3 completely, and then incubated
for 5 min at 70°C. The columns were placed into new 1 .5 mL microcentrifuge tubes, and 30 µL
Buffer NE were added. After incubating at room temperature for 1 min, tubes were centrifuged
for 1 min at 1 1 ,000 x g, and the eluent was collected. Samples were stored at -20°C until used.

Ligation of Adapter Sequences to Purified DNA Digests
Adapters were ligated to each sample of purified DNA digest according to the
instructions in the Genome Walker kit (Clontech). The reaction mixtures contained 4.8 µL
purified DNA digest, 1 .9 µL Genome Walker Adaptor (25 µM), 0.8 µL of 1 Ox Ligation Buffer,
and 0.5 µL T4 DNA Ligase (6 units/µL). Samples were incubated at 1 6°C overnight in a thermal
cycler, then incubated for 5 min at 70°C to stop the reaction. To each tube, 32 µL of TE buffer
(10/1 pH 7.5) were added. The tubes were vortexed gently for 10-15 s, and then stored at -20°C
until used.

Gel Electrophoresis
Gel electrophoresis was performed using 1 .2% agarose gels. A volume of 4 µL of Gel
Red intercalating nucleic acid stain was added to the dissolved gel mixture before pouring it into
the gel tray. Gels were run at 90-1 10 V for about one hour. Time varied depending on the degree
of separation of the bands. A Bio-Rad imaging system was used to read the gels.
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Results and Discussion
To verify the presence of FeLV-B in the tissue samples collected, PCR using primers
BSF and BSR was completed and gel electrophoresis was used. Figure 3 shows an image of the
agarose gel obtained from this process. All lanes, except for the liver in lane 2, showed bands
about 400 bp with regards to the reference ladders in lanes 4 and 8, confirming the presence of
FeLV. The reason for the liver tissue sample not producing a band was unclear. Further PCR and
gel pictures showed the virus within the tissue sample.
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Figure 3: Primary PCR from tissue samples. To verify the presence of
FeLV in the extracted tissue samples, Primary PCR was done using
primer 85F/B5R. Lanes are as followed: I - Spleen, 2- Liver, 3Mammary Tumor, 4- Reference ladders, 5- Lymph, 6- Kidney, 7- Brain.
Post-PCR cleanup was done on all samples to remove any excess primers. Before sending
the samples for sequencing at The University of Michigan Core DNA Sequencing Lab, the
concentrations of the samples were adjusted to fit the sequencing criteria. By using Nucleotide
Blast provided by National Center for Biotechnology Information website, the virus within the
tissue samples was determined to match verified FeLV-B sequences more closely than FeLV-A,
-C, or -T, as shown in Figure 4.
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Figure 4: Sequencing Alignment. These images compare sequences obtained from extracted
DNA from tumor sample. The sequences are aligned with known FeLV-A sequence, Rickard-A,
and FeLV-B Glasgow sequence-B, KOI209. The known sequences are imputed as Query and the
sample DNA is the subject. These results show that our sample is more closely correlated with
FeLV-B than it is to FeLV-A.
Sequencing chromatograms were visualized with the computer program Finch TV.
Figure 5 shows the sequence chromatogram obtained for the mammary tumor. Most of the peaks
have good resolution with the exception of those within black boxes. These are peaks where the
original sequence was given an "N" instead of a base pair due to multiple peaks being present.
Because of this, it was thought that during PCR, multiple insertions were being amplified, which
is consistent with the variable nature of the virus, and the fact that the majority of the sequencing
peaks are clearly single-bases, with a good signal-to-noise ratio.
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Figure 5: Chromatogram Sequence. Sequencing chromatogram for the amplicon of FeLV-B obtained
from genomic DNA extracted from mammary tumor tissue sample.

Using the computer program ClustalX, both native and reverse complement sequences of
tissue samples were aligned, Figure 6. Table 5 shows the tissue samples with corresponding
reference numbers. The majority of the tissue samples line up very closely to each other, with a
few exceptions. There are quite a few sites where there is no nucleotide base, but rather an "N."
These sites correspond to areas where multiple peaks were present in the chromatograms. The
tumor's samples contained more variation than the others and so further investigation into their
sequencing was completed.

12

�•lz,,2
24 l2ee,
24l218D
2432111
243289'
24l2114
24l211'
2432191
24l211 1
24321 90
24 l21U...J<C
2431'02..I\C
24l21'2,...J<C
24328'6,J.C
24llll,1J.C'
20201..,J<C
202'03._J\C:
2u21,3J\c
2•:ue,•Jt.c
2020,_,.c

----------------·------------------------------ ·------------------·----------- - --- ·-�
•••••••···············••••••••••••••••••••
----------------------------------------- -----------------------------·-----------·
------------------------------------------------------------ - ------------ -----------------------------------------------------------------------------------------------------------------------••

Figure 6: ClustalX alignment of tissue samples. Both native and reverse complement of the
tissue samples were aligned together. See Table 5 for tissue sample with corresponding reference
numbers.

Table 5: Sequence reference numbers with corresponding tissue.
2432880/2432892
24328 1/2432893
2432882/ 2432894
2432883/2432895
2432884/2432896
2432885/2432897
2432886/2432898
2432887/2432899
2432890/2432902
2432891/2432903

Spleen
Spleen
Tumor
Tumor
Kidney
Kidnev
Brain
Brain
Lymoh
Lymph

For the tumor samples, the multiple peaks throughout the sequences were closely
examined. For each pair, one of the nucleotides observed in the chromatogram was one that
matched the other tissue samples. The overlapping nucleotide at each position differentiated the
tumor samples from the other tissues. The sequences of the tumor samples were completed by
replacing each "N" with one of the two nucleotide options. Those that would make the sequence
different than the other samples were chosen. The original sequences of the tumor and the edited
sequences are as follows:
2432894- Tumor Original

TTTTCCCGAGTAACACCTCACCATTCCCAAGGCAACGGAGGCACCCCAGGTATAACTCTTGTTAATGCCTCCATTGCCCCTCTAAGTACCCC
TGTCACCCCCGCAAGTCCCAAACGTATNGGGACAGGANATAGGTTAATAAATTTAGTGCAGGGGACATATCTAGCTTTAAATGTCACTGACC
CCAACAAAACTAAAGACTGTTGGCTCTGNCTGGTTTCNCGACCGCCCTATTATGAAGGNATTGCGGTNTTGGGNAATTACAGCAACCAAAC
NANCCCNCCCCCATCCTGCCTATCNGATCCNCAACATTAANCTGACTATATCAGAAGTTCCCGGCAGGTTGNN
2432894- Tumor Edited

TTTTCCCGAGTAACACCTCACCATTCCCAAGGCAACGGAGGCACCCCAGGTATAACTCTTGTTAATGCCTCCATTGCCCCTCTAAGTACCCC
TGTCACCCCCGCAAGTCCCAAACGTATTGGGACAGGAGATAGGTTAATAAATTTAGTGCAGGGGACATATCTAGCTTTAAATGTCACTGACC
CCAACAAAACTAAAGACTGTTGGCTCTGCCTGGTTTCTCGACCGCCCTATTATGAAGGGATTGCGGTCTTGGGTAATTACAGCAACCAAAC
AAACCCTCCCCCATCCTGCCTATCTGATCCGCAACATTAAGCTGACTATATCAGAAGTTCCCGGCAGGTTGNN
243289S. Tumor Original

TTTTTCCCGAGTAACACCTCACCATTCCCAAGGCAACGGAGGCACCCCAGGTATAACTCTTGTTAATGCCTCCATTGCCCCTCTAAGTACCC
CTGTCACCCCCGCAAGTCCCAAACGTATNGGGACAGGANATAGGTTAATAAATTTAGTGCAGGGGACATATCTAGCTTTAAATGTCACTNAC
CCCAACAAAACTAAAGACTGTTGGCTCTGNCTGGTTTCNCGACCGCCCTATTATGAAGGNATTGCGGTNTTGGGCAATTACAGCAACCAAA
CNAACCCNCCCCCATCCTGCCTATCNGATCCNCAACATAANCTGACTATATCNGAAGTTCCGGCAAGTTGN

2432895-Tumor Edited

TTTTTCCCGAGTAACACCTCACCATTCCCAAGGCAACGGAGGCACCCCAGGTATAACTCTTGTTAATGCCTCCATTGCCCCTCTAAGTACCC
CTGTCACCCCCGCAAGTCCCAAACGTATTGGGACAGGAGATAGGTTAATAAATTTAGTGCAGGGGACATATCTAGCTTTAAATGTCACTGAC
CCCAACAAAACTAAAGACTGTTGGCTCTGCCTGGTTTCTCGACCGCCCTATTATGAAGGGATTGCGGTCTTGGGCAATTACAGCAACCAAA
cAAAcccTcccccATCCTGCCTATCTGATCCGCAACATAAGCTGACTATATCAGAAGTTCCGGCAAGTTGN
Figure 7 shows the edited sequences aligned using ClustalX. Both native and reverse
complement sequences of tissue samples were aligned with four reference sequences ofFeLV-A,
top four sequences, and three reference sequences ofFeLV-8, 5th-7th sequences. When
comparing tissue samples sequences to the references, it appears that they are more closely
similar to the references of FeLV-8 rather than FeLV-A; tissue samples do not have gaps of the
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sequences missing towards the beginning as do the FeLV-A references. Again, this is
verification that the tissue samples contain feline leukemia virus that is more likely the B strain
than the A strain. Positive verification can be obtained by viral interference assay.
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Figure 7: ClustalX alignment of tissue samples. FeLV-A and FeLV-B reference sequences aligned with
edited tumor sequences and other tissue sample sequences.

After review of the amino acid alignment, it appears the experimental sequences closely
match those of F eLV-B and endogenous FeLV. The reading frame for the sequence change that
contained the C to T change was read as CCT, which codes proline (P). This amino acid for the
tumor sequences are boxed, inFigure 8. It appears that the change did not differentiate the
sequence from the others. Had a C been placed in the sequence instead of a T, the reading frame
would have produced CCC, which also codes for proline. This change was a silent mutation. It is
marked as ( a) inFigure 8.
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Figure 8: Alignment of amino acids. Alignment of deduced amino acids from the tumor DNA sequences

shown in Figure 7.
The two boxes labeled (b) on the amino acid sequence in Figure 8 also show a mutation,
but they are not silent. When looking at the corresponding reading frame for these two
sequences, they contained a change from A to G, coding for aspartic acid rather than asparagine.
When looking at the natural isolate of FeLV-8 obtained from the NCBI databases, the same
change can be seen. To see how this amino acid change affects the virus, further research will
need to be done.
Other changes in the nucleotide sequence did not produce any other noticeable changes in
the amino acid sequences, leading to the conclusion that other silent mutations were made. Of
note, the last box (labeled c) on the amino acid sequence in Figure 8 shows that of ten amino acid
sequences aligned at that position, six different residues are present. When looking at the
nucleotide sequences in Figure 7, the bases that code in this region are highlighted in a white
box. The reason for the variance in the sequences is unclear, but the position of the mutation in
the envelope gene is consistent with samples determined previously by other research groups.

Conclusion and Future Directions
FeLV-8 sequences were successfully amplified from five of the six tissue extracts. New
primers will be designed based on these sequencing results and will be used during the primer
walking process in order to sequence the entire proviral insert. Sequencing the whole proviral
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insert can lead to better understanding of how the insertion site is related to the progression of
the symptoms.
To further investigate the primary PCR products, the samples will be cloned and
transformed, followed by sequencing, as each isolated colony will contain a single variant of the
virus. This will allow for testing of the hypothesis that multiple insertion sites were being
amplified during this process.
Variations in the tumor samples were observed in the nucleotide sequences and when
these variations were altered, mutations within the amino acid sequences were observed.
Variations were not seen in the other tissue samples. This supports the original hypothesis that
tumor samples would show mutations and/or rearrangements not observed in other tissues.
Additional studies of the amino acid sequence will be done to better understand the possible
mutations that occurred when altering the nucleotide sequence. Likewise, further work would be
needed to determine the effect of these mutations on the disease progression and outcome.
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